Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
Pfizer, Arvinas Delay Late-stage Trial for Breast Cancer Therapy
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Biggest Stock Movers Tuesday: SMCI, INCY, and More
Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With...